Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (FRA:GU5)

Market Cap	4.75B -15.2%
Revenue (ttm)	9.28B +1.5%
Net Income	357.55M -12.8%
EPS	0.22 -12.8%
Shares Out	n/a
PE Ratio	13.28
Forward PE	14.19
Dividend	0.10 (4.85%)
Ex-Dividend Date	Aug 29, 2025

Volume	n/a
Average Volume	212
Open	2.020
Previous Close	2.020
Day's Range	1.990 - 2.020
52-Week Range	1.840 - 2.300
Beta	n/a
RSI	42.30
Earnings Date	Mar 21, 2026

About FRA:GU5

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, import, and export of Western and Chinese medicines, medical instruments, pharmaceutical products, medical apparatus, and healthcare products; research...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 1997
• Employees: 27,425
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GU5

Financial Performance

In 2024, FRA:GU5's revenue was 74.99 billion, a decrease of -0.69% compared to the previous year's 75.52 billion. Earnings were 2.84 billion, a decrease of -30.09%.

Financial numbers in CNY